Literature DB >> 23188539

Liver transplantation for primary hyperoxaluria type 1: a single-center experience during two decades in Japan.

Tomohide Hori1, Hiroto Egawa, Toshimi Kaido, Kohei Ogawa, Shinji Uemoto.   

Abstract

BACKGROUND: Primary hyperoxaluria type-1 (PH1) is an autosomal recessive disorder caused by impaired activity of hepatic peroxisomal alanine-glyoxylate aminotransferase that leads to end-stage renal disease (ESRD). A definitive diagnosis is often delayed until ESRD appears. Based on the etiology, liver transplantation (LT) seems to be the definitive treatment. PATIENTS AND METHODS: Three PH1 patients underwent LT at our institution during two decades.
RESULTS: Two of the patients had family histories of cryptogenic ESRD. All three showed disease onset in childhood, but the definitive diagnosis was delayed in two cases (17 and 37 years of age). These delayed cases resulted in ESRD, and hemodialysis (HD) had been introduced before LT. One patient received domino LT, and the other two underwent living-donor LT (LDLT). One patient finally died of sepsis, and was unable to receive a kidney transplantation (KT) after the domino LT. One patient did not show ESRD, and did not have to undergo KT after LDLT, although extracorporeal shock wave lithotripsy was required for residual ureterolithiasis (8 years after LDLT). The third patient had an uneventful course after LDLT and received living-donor KT from the same donor 8 months after LDLT. Subsequently, HD was successfully withdrawn.
CONCLUSIONS: Establishment of a definitive diagnosis of PH1 is essential. If a methodology for early diagnosis and an intensive care strategy for neonates and infants during the waiting time become well-established, a timely and preemptive LT alone can provide a good chance of cure for PH1 patients.

Entities:  

Mesh:

Year:  2013        PMID: 23188539     DOI: 10.1007/s00268-012-1867-7

Source DB:  PubMed          Journal:  World J Surg        ISSN: 0364-2313            Impact factor:   3.352


  29 in total

1.  Domino liver transplantation using FAP grafts. HUC experience--hopes and realities.

Authors:  A J Furtado
Journal:  Amyloid       Date:  2003-08       Impact factor: 7.141

2.  Primary hyperoxaluria type 1: gene therapy by liver transplantation.

Authors:  Neville V Jamieson; Katharine A Jamieson
Journal:  Transplantation       Date:  2009-05-15       Impact factor: 4.939

3.  Does a positive lymphocyte cross-match contraindicate living-donor liver transplantation?

Authors:  Tomohide Hori; Shinji Uemoto; Yasutsugu Takada; Fumitaka Oike; Yasuhiro Ogura; Kohei Ogawa; Aya Miyagawa-Hayashino; Kimiko Yurugi; Justin H Nguyen; Yukinobu Hori; Feng Chen; Hiroto Egawa
Journal:  Surgery       Date:  2010-01-21       Impact factor: 3.982

4.  Early renal failure after domino liver transplantation using organs from donors with primary hyperoxaluria type 1.

Authors:  Fuat H Saner; Juergen Treckmann; Johann Pratschke; Helmut Arbogast; Axel Rahmel; Udo Vester; Andreas Paul
Journal:  Transplantation       Date:  2010-10-15       Impact factor: 4.939

5.  Kidney transplantation in primary oxalosis: data from the EDTA Registry.

Authors:  M Broyer; F P Brunner; H Brynger; S R Dykes; J H Ehrich; W Fassbinder; W Geerlings; G Rizzoni; N H Selwood; G Tufveson
Journal:  Nephrol Dial Transplant       Date:  1990       Impact factor: 5.992

Review 6.  Hyperoxaluria and systemic oxalosis: current therapy and future directions.

Authors:  Amy E Bobrowski; Craig B Langman
Journal:  Expert Opin Pharmacother       Date:  2006-10       Impact factor: 3.889

7.  How transplant surgeons can overcome the inevitable insufficiency of allograft size during adult living-donor liver transplantation: strategy for donor safety with a smaller-size graft and excellent recipient results.

Authors:  Tomohide Hori; Yasuhiro Ogura; Kohei Ogawa; Toshimi Kaido; Hajime Segawa; Hideaki Okajima; Takayuki Kogure; Shinji Uemoto
Journal:  Clin Transplant       Date:  2012 May-Jun       Impact factor: 2.863

8.  Primary hyperoxaluria (type I): attempted treatment by combined hepatic and renal transplantation.

Authors:  R W Watts; R Y Calne; R Williams; M A Mansell; N Veall; P Purkiss; K Rolles
Journal:  Q J Med       Date:  1985-10

9.  Present status of ABO-incompatible living donor liver transplantation in Japan.

Authors:  Hiroto Egawa; Satoshi Teramukai; Hironori Haga; Minoru Tanabe; Masanori Fukushima; Motohide Shimazu
Journal:  Hepatology       Date:  2008-01       Impact factor: 17.425

10.  Two-step transplantation for primary hyperoxaluria: cadaveric liver followed by living donor related kidney transplantation.

Authors:  Ivone Malla; Philippe A Lysy; Nathalie Godefroid; Françoise Smets; Jaques Malaise; Raymond Reding; Etienne M Sokal
Journal:  Pediatr Transplant       Date:  2008-11-10
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.